{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:14:46Z","timestamp":1765887286682},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,12,14]],"date-time":"2010-12-14T00:00:00Z","timestamp":1292284800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1038\/sj.bjc.6606051","type":"journal-article","created":{"date-parts":[[2010,12,14]],"date-time":"2010-12-14T21:06:34Z","timestamp":1292360794000},"page":"265-271","source":"Crossref","is-referenced-by-count":16,"title":["Phase I trial of docetaxel, cisplatin and concurrent radical radiotherapy in locally advanced oesophageal cancer"],"prefix":"10.1038","volume":"104","author":[{"given":"F L","family":"Day","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Leong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Ngan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Jefford","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J R","family":"Zalcberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Rischin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"McKendick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A D","family":"Milner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Di Iulio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Matera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Michael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,12,14]]},"reference":[{"key":"BF6606051_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1200\/JCO.1997.15.1.277","volume":"15","author":"M Al-Sarraf","year":"1997","unstructured":"Al-Sarraf M, Martz K, Herskovic A, Leichman L, Brindle JS, Vaitkevicius VK, Cooper J, Byhardt R, Davis L, Emami B (1997) Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: An intergroup study. J Clin Oncol 15: 277\u2013284","journal-title":"J Clin Oncol"},{"key":"BF6606051_CR2","first-page":"2001","volume":"20","author":"HG Chun","year":"2001","unstructured":"Chun HG, Puccio CA, Mittelman A (2001) Weekly docetaxel and continuous infusion (CI) 5-fluorouracil (5-FU) in elderly patients (Pts) with cancer of the stomach and distal esophagus. Proc Am Soc Clin Oncol 20: 2001 (abstract 645)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6606051_CR3","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/BF02993858","volume":"13","author":"AI Einzig","year":"1996","unstructured":"Einzig AI, Neuberg D, Remick SC, Karp DD, O\u2019Dwyer PJ, Stewart JA, Benson III AB (1996) Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 13: 87\u201393","journal-title":"Med Oncol"},{"key":"BF6606051_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s12094-007-0032-5","volume":"9","author":"A Font","year":"2007","unstructured":"Font A, Arellano A, Fern\u00e1ndez-Llamazares J, Casas D, Boix J, Cardenal J, Margeli M, Manzano JL, Abad A, Rosell R (2007) Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer. Clin Trans Oncol 9: 177\u2013182","journal-title":"Clin Trans Oncol"},{"key":"BF6606051_CR5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/S1470-2045(07)70039-6","volume":"8","author":"V Gebski","year":"2007","unstructured":"Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J, Simes J (2007) Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8: 226\u2013234","journal-title":"Lancet Oncol"},{"key":"BF6606051_CR6","doi-asserted-by":"publisher","first-page":"2164","DOI":"10.1200\/JCO.1998.16.6.2164","volume":"16","author":"JD Hainsworth","year":"1998","unstructured":"Hainsworth JD, Burris HA, Erland JB, Thomas M, Greca FA (1998) Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16: 2164\u20132168","journal-title":"J Clin Oncol"},{"key":"BF6606051_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1023\/A:1014476602804","volume":"20","author":"EI Heath","year":"2002","unstructured":"Heath EI, Urba A, Marshall J, Piantadosi S, Forastiere AA (2002) Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Invest New Drugs 20: 95\u201399","journal-title":"Invest New Drugs"},{"key":"BF6606051_CR8","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1056\/NEJM199206113262403","volume":"326","author":"A Herskovic","year":"1992","unstructured":"Herskovic A, Martz K, Al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, Cooper J, Byhardt R, Davis L, Emami B (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326: 1593\u20131598","journal-title":"N Engl J Med"},{"key":"BF6606051_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59: 225\u2013249","journal-title":"CA Cancer J Clin"},{"key":"BF6606051_CR10","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1038\/sj.bjc.6601624","volume":"90","author":"H Katayama","year":"2004","unstructured":"Katayama H, Ueoka H, Kiura K, Tabata M, Kozuki T, Tanimoto M, Fujiwara T, Tanaka N, Date H, Aoe M, Shimizu N, Takemoto M, Hiraki Y (2004) Preoperative concurrent chemoradiotherapy with cisplatin and docetaxel in patients with locally advanced non-small-cell lung cancer. Br J Cancer 90: 979\u2013984","journal-title":"Br J Cancer"},{"key":"BF6606051_CR11","first-page":"A1540","volume":"38","author":"H Kawamura","year":"1997","unstructured":"Kawamura H, Terashima M, Ikeda K, Takiyama I, Sasaki N, Ishida K, Saito K (1997) Antitumour activities of Taxotere and Taxol against human esophageal cancer. Proc Amer Assoc Cancer Res 38: A1540","journal-title":"Proc Amer Assoc Cancer Res"},{"key":"BF6606051_CR12","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1038\/sj.bjc.6601217","volume":"89","author":"K Kiura","year":"2003","unstructured":"Kiura K, Ueoka H, Segawa Y, Tabata M, Kamei H, Takigawa N, Hiraki S, Watanabe Y, Bessho A, Eguchi K, Okimoto N, Harita S, Takemoto M, Hiraki Y, Harada M, Tanimoto M (2003) Phase I\/II study of docetaxel and cisplatin with concurrent thoracic radiation therapy for locally advanced non-small-cell lung cancer. Br J Cancer 89: 795\u2013802","journal-title":"Br J Cancer"},{"key":"BF6606051_CR13","first-page":"647","volume":"28","author":"E Laack","year":"2005","unstructured":"Laack E, Andritzky B, Durk H, Burkholder I, Edler L, Schuch G, Boeters I, Gorn M, Lipp R, Horst H, Popp J, Hossfeld DK (2005) Docetaxel and cisplatin as first-line treatment for patients with metastatic esophageal cancer: a pilot study. Onkologie 28: 647\u2013650","journal-title":"Onkologie"},{"key":"BF6606051_CR14","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/sj.bjc.6601168","volume":"89","author":"F Lordick","year":"2003","unstructured":"Lordick F, von Schilling C, Bernhard H, Hennig M, Bredenkamp R, Peschel C (2003) Phase II trial of irinotecan plus docetaxel in cisplatin-pretreated relapsed or refractory oesophageal cancer. Br J Cancer 89: 630\u2013633","journal-title":"Br J Cancer"},{"key":"BF6606051_CR15","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1038\/sj.bjc.6602645","volume":"92","author":"S Lorenzen","year":"2005","unstructured":"Lorenzen S, Duyster J, Lersch C, von Delius S, Henning M, Bredenkamp R, Peschel C, Lordick F (2005) Capecitabine plus docetaxel every 3 weeks in first- and second-line metastatic oesophageal cancer: final results of a phase II trial. Br J Cancer 92: 2129\u20132133","journal-title":"Br J Cancer"},{"key":"BF6606051_CR16","first-page":"2431","volume":"3","author":"KA Mason","year":"1997","unstructured":"Mason KA, Hunter NR, Milas M, Abbruzzese JL, Milas L (1997) Docetaxel enhances tumour radioresponse in vivo. Clin Cancer Res 3: 2431\u20132438","journal-title":"Clin Cancer Res"},{"key":"BF6606051_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1200\/JCO.1998.16.1.159","volume":"16","author":"AM Mauer","year":"1998","unstructured":"Mauer AM, Masters GA, Haraf DJ, Hoffman PC, Watson SM, Golomb HM, Vokes EE (1998) Phase I study of docetaxel with concomitant thoracic radiation therapy. J Clin Oncol 16: 159\u2013164","journal-title":"J Clin Oncol"},{"key":"BF6606051_CR18","first-page":"2000","volume":"19","author":"A Mauer","year":"2000","unstructured":"Mauer A, Haraf D, Ferguson M, Posner M, Sandler A, Kesler K, Hoffman P, Rudin C, Talabay K, Vokes E (2000) Docetaxel-based combined modality therapy for locally advanced carcinoma of the esophagus and gastric cardia. Proc Am Soc Clin Oncol 19: 2000 (abstract 954)","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF6606051_CR19","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jtcvs.2009.07.069","volume":"138","author":"RA Meguid","year":"2009","unstructured":"Meguid RA, Hooker CM, Taylor JT, Kleinberg LR, Cattaneo SM, Sussman MS, Yang SC, Heitmiller RF, Forastiere AA, Brock MV (2009) Recurrence after neoadjuvant chemoraditaion and surgery for esophageal cancer: Does the pattern of recurrence differ for patients with complete response and those with partial or no response? J Thorac Cardiovasc Surg 138: 1309\u20131317","journal-title":"J Thorac Cardiovasc Surg"},{"key":"BF6606051_CR20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/S0169-5002(02)00448-8","volume":"39","author":"R Mudad","year":"2003","unstructured":"Mudad R, Ramsey M, Kovitz K, Curiel TJ, Hartz R, Nedzi LL, Weiner RS, Zakris EL (2003) Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: a dose finding study. Lung Cancer 39: 173\u2013177","journal-title":"Lung Cancer"},{"key":"BF6606051_CR21","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1093\/annonc\/mdi207","volume":"16","author":"F Pasini","year":"2005","unstructured":"Pasini F, de Manzoni G, Pedrazzani C, Grandinetti A, Durante E, Gabbani M, Tomezzoli A, Griso C, Guglielemi A, Pelosi G, Maluta S, Cetto GL, Cordiano C (2005) High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy. Ann Oncol 16: 1133\u20131139","journal-title":"Ann Oncol"},{"key":"BF6606051_CR22","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1093\/annonc\/mdp045","volume":"20","author":"T Ruhstaller","year":"2009","unstructured":"Ruhstaller T, Widmer L, Schuller JC, Roth A, Hess V, Mingrone W, von Moos R, Borner M, Pestalozzi BC, BalmerMajno S, K\u00f6berle E, Terraciano L, Schnider A, Bodis S, Popescu R (2009) Multicenter phase II trial of preoperative induction chemotherapy followed by chemoradiation with docetaxel and cisplatin for locally advanced esophageal carcinoma (SAKK 75\/02). Ann Oncol 20: 1522\u20131528","journal-title":"Ann Oncol"},{"key":"BF6606051_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S0360-3016(01)01739-4","volume":"52","author":"H-G Wu","year":"2002","unstructured":"Wu H-G, Bang Y-J, Choi EK, Ahn YC, Kim YW, Lim T-H, Suh C, Park K, Park CI (2002) Phase I study of weekly docetaxel and cisplatin concurrent with thoracic radiotherapy in stage III non-small-cell lung cancer. Int J Rad Onc Biol Phys 52: 75\u201380","journal-title":"Int J Rad Onc Biol Phys"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/6606051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6606051","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/6606051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T12:48:47Z","timestamp":1684414127000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/6606051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,14]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["BF6606051"],"URL":"https:\/\/doi.org\/10.1038\/sj.bjc.6606051","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,14]]}}}